Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.

Foti RS, Pearson JT, Wong SL, Zalikowski JA, Boudreaux MD, Prokop SP, Davis JA, Banfield C, Emery MG, Rock DA, Wahlstrom JL, Wienkers LC, Amore BM.

Drug Metab Dispos. 2012 Dec;40(12):2239-49. doi: 10.1124/dmd.112.047928. Epub 2012 Aug 28.

3.

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.

Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, Chon Y, Budelsky AL, Lin J, Lin SL.

J Allergy Clin Immunol. 2013 Feb;131(2):339-45. doi: 10.1016/j.jaci.2012.10.013. Epub 2012 Nov 20.

PMID:
23174659
4.

In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.

Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2011 Sep;39(9):1658-67. doi: 10.1124/dmd.111.039776. Epub 2011 Jun 14.

5.

Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.

Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G.

Drug Metab Dispos. 2008 May;36(5):851-62. doi: 10.1124/dmd.107.019539. Epub 2008 Feb 6.

6.

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

Baldwin SJ, Clarke SE, Chenery RJ.

Br J Clin Pharmacol. 1999 Sep;48(3):424-32.

7.

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.

Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258. Epub 2012 Jul 30.

8.

In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.

Albrecht W, Unger A, Nussler AK, Laufer S.

Drug Metab Dispos. 2008 May;36(5):894-903. doi: 10.1124/dmd.108.020347. Epub 2008 Feb 11.

9.

The xenobiotic inhibitor profile of cytochrome P4502C8.

Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO.

Br J Clin Pharmacol. 2000 Dec;50(6):573-80.

11.

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.

Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.

J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. doi: 10.1124/jpet.109.161893. Epub 2009 Nov 4.

12.

Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.

Dean BJ, Chang S, Silva Elipe MV, Xia YQ, Braun M, Soli E, Zhao Y, Franklin RB, Karanam B.

Drug Metab Dispos. 2007 Feb;35(2):283-92. Epub 2006 Nov 28.

13.

Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.

Johnson MG, Liu JJ, Li AR, van Lengerich B, Wang S, Medina JC, Collins TL, Danao J, Seitz L, Willee A, D'Souza W, Budelsky AL, Fan PW, Wong SG.

Bioorg Med Chem Lett. 2014 Jul 1;24(13):2877-80. doi: 10.1016/j.bmcl.2014.04.092. Epub 2014 May 4.

PMID:
24825301
14.

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Polasek TM, Sadagopal JS, Elliot DJ, Miners JO.

Eur J Clin Pharmacol. 2010 Mar;66(3):275-83. doi: 10.1007/s00228-009-0760-2. Epub 2009 Dec 11.

PMID:
20012430
15.

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].

17.

Biotransformation of fluticasone: in vitro characterization.

Pearce RE, Leeder JS, Kearns GL.

Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24.

18.

Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.

Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, Humphreys WG.

Drug Metab Dispos. 2007 Jan;35(1):139-49. Epub 2006 Oct 24.

19.

Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543.

Khojasteh-Bakht SC, Rossulek MI, Fouda HG, Prakash C.

Xenobiotica. 2003 Dec;33(12):1201-10.

PMID:
14742142
20.

Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.

Pettipher R, Vinall SL, Xue L, Speight G, Townsend ER, Gazi L, Whelan CJ, Armer RE, Payton MA, Hunter MG.

J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. doi: 10.1124/jpet.111.187203. Epub 2011 Nov 21.

Supplemental Content

Support Center